Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeEfficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationThe case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranReversal of oral anticoagulationNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndromeGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced agePharmacometric characterization of dabigatran hemodialysisDirect thrombin inhibitors.Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillationAnticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timePharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.Enhanced elimination of dabigatran through extracorporeal methods.Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.Stroke prevention in atrial fibrillation: concepts and controversiesNovel anticoagulants in atrial fibrillation stroke preventionDabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.Should women receive left ventricular assist device support?: findings from INTERMACS.Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsConcerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES studyExtracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experiencePractical management of new oral anticoagulants after total hip or total knee arthroplasty.Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsRecent developments in the use of oral anticoagulants.New antithrombotic drugs.
P2860
Q24185813-A6098C55-0AAA-452B-BE25-0637FC023A10Q26749141-00CC32B4-0FA8-4A3B-AACD-75219BC360FFQ26776239-3343A077-2A47-4968-B0E2-7CB6B1AF0CB7Q26783457-FD504312-6AB9-4589-9E42-1B9B7D1196F4Q26799710-7D35429E-4F2E-4422-87C3-03D61C8A6299Q26827835-B67BFBF2-5794-47B8-AAFF-1C982921550DQ28067420-A4276F70-128C-400B-BB7E-C5AB6AE93DDAQ28076077-AD68EBCC-B232-4F62-9F0D-B1E9CD965FD6Q28079930-9A7D280F-EDEE-492C-ACC4-C08E64AB7CF0Q29584461-6F8D9B97-2B18-4D29-B900-0EFC07EDB3D9Q33393692-19AACFEA-CB46-41B4-9427-EE77CB0740A8Q33804810-73755FCB-BBF4-4B8B-AA48-36C2244FDB18Q33847039-04B189AC-E878-44F6-93F0-86F67F7E7BC3Q34017336-ED59A5D2-516D-44D7-B03D-526F8AE6B243Q34206252-1FDFB06F-FDE0-48F0-9DA4-0001097A833BQ34252907-9E19D626-A472-4E20-99E2-AF8D37999E57Q34571082-F9861485-6EFC-4467-B6A7-B088706E8470Q34611004-7CFC48D7-EC42-4608-BADF-8606CE41B6B1Q34638063-9D92A5C5-3A2A-4364-99C3-6AD7C904FD96Q34651036-B6708EE2-B2DF-49B1-A0C4-6EBF0C3AE7B2Q34651051-79D3937B-865E-4F16-82F1-2566F3887C46Q34691799-A69F005B-3292-45E3-99AF-076F50376D75Q35210137-9316E842-215C-4760-B456-04E58EF16A1AQ35975334-50205921-F53A-4264-998A-54AB1D767DA7Q36336046-A5C87BB9-EBB1-4489-8203-A8CC42A6AF9BQ36382375-66833E7F-BA43-48FA-8F03-375E8FC3D378Q36443814-AC05B5E5-5623-43CB-AE96-5BDCD366184BQ36548878-CED89B09-1D57-40FF-A884-15D8E547B0D3Q36793794-19A919A9-CC32-43D5-869C-BC0E4E1F22FAQ36841028-E1CD9811-E6FA-4771-BAB8-B211C70DD9C1Q36874702-BE042F3A-37DF-4E75-BA43-B3BC4299B8E2Q36875879-3EF04409-8768-4AC2-9F8E-808EBA213FC1Q37014482-123E01BB-9FD5-4697-A83C-01457E2A5CE6Q37148702-45C0C451-C781-4994-98CC-50350B8FBEE7Q37226300-56BFC700-D2AC-4324-8B9F-8740745A88ABQ37246953-812FDA91-1281-4787-ACAE-E2985162C3A7Q37338120-0946C928-E664-4D7B-A412-07B971CA43B8Q37495788-D1EEE4B8-15B9-4579-A751-8A0E3B9622C1Q37528463-44DD393D-41A9-430F-86FD-6A31656AEF38Q37530424-BC51DA4F-5BE1-4802-94B0-A855D0BCD6E0
P2860
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@ast
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@en
type
label
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@ast
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@en
prefLabel
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@ast
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@en
P2093
P1476
Pharmacokinetics and pharmacod ...... n in healthy elderly subjects.
@en
P2093
Hildegard Stähle
Joachim Stangier
Karin Rathgen
Reinhold Fuhr
P356
10.2165/00003088-200847010-00005
P577
2008-01-01T00:00:00Z
P6179
1039261332